Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,369.44
    +201.37 (+0.50%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,449.71
    +115.97 (+0.16%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,541.31
    +10.71 (+0.70%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amphastar Pharmaceuticals (AMPH) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Amphastar Pharmaceuticals is a member of the Medical sector. This group includes 1144 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amphastar Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past 90 days, the Zacks Consensus Estimate for AMPH's full-year earnings has moved 20.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

ADVERTISEMENT

According to our latest data, AMPH has moved about 63.7% on a year-to-date basis. At the same time, Medical stocks have lost an average of 2.9%. This means that Amphastar Pharmaceuticals is outperforming the sector as a whole this year.

Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. The stock's year-to-date return is 11.6%.

The consensus estimate for Arbutus Biopharma's current year EPS has increased 22.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, which includes 17 individual stocks and currently sits at #103 in the Zacks Industry Rank. Stocks in this group have gained about 3.3% so far this year, so AMPH is performing better this group in terms of year-to-date returns.

On the other hand, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry. This 552-stock industry is currently ranked #98. The industry has moved -6.7% year to date.

Going forward, investors interested in Medical stocks should continue to pay close attention to Amphastar Pharmaceuticals and Arbutus Biopharma as they could maintain their solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report

Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research